Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer
Metrics: PDF 3509 views | HTML 1981 views | ?
Lushuai Yao1,2,*, Shancheng Ren3,*, Minjie Zhang1,2,*, Fengxia Du1, Yasheng Zhu3, Hui Yu1,2, Chenyu Zhang1, Xiaohua Li1, Caiyun Yang1, Huixian Liu1, Dong Wang1,2, Hao Meng1,2, Shuang Chang1,2, Xiao Han1,2, Yinghao Sun3 and Yingli Sun1
1 Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
2 University of Chinese Academy of Sciences, Beijing, China
3 Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China
* These authors have contribute equally to this work
Yingli Sun, email:
Yinghao Sun, email:
Keywords: DNA methylation, prostate cancer, Y-chromosome, biomarker
Received: April 01, 2015 Accepted: September 26, 2015 Published: October 16, 2015
As a diagnostic biomarker, prostate special antigen (PSA) tests always generate false positive results and lead to unnecessary and/or repeat biopsies. Therefore, there is an urgent need for developing more sensitive, specific diagnostic biomarkers. We epigenotyped methylated sites in cancer tissues and adjacent normal tissues from 66 patients. In comparation with normal adjacent tissues, we observed that there were 6 aberrant methylation sites in prostate cancer tissues on the Y-chromosome. We further performed pyrosequencing using urine of PCa patients and we identified one methylated site (cg05163709) as a potential biomarker. We evaluated the predictive capacity of the aberrant methylated sites using the area under receiver operating characteristic (ROC) curve (AUC). The ROC analysis showed a higher AUC for cg05163709 (0.915) than prostate-specific antigen (PSA, 0.769). These results indicated that aberrant DNA methylation of cg05163709 on the Y-chromosome could serve as a potential diagnostic biomarker with high sensitivity and specificity.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.